Johnson & Johnson completes first cases with OTTAVA robotic surgical system

The Robot Report Staff
2025-04-16 13:53:00
www.therobotreport.com

While J&J has kept its Ottava robot under wraps, it said the system offers surgical teams the ability to adapt to clinical workflows and individual patient needs. | Source: Johnson & Johnson

Johnson & Johnson MedTech this week announced that it has completed the first cases in the clinical trial for its OTTAVA Robotic Surgical System. The cases mark the first clinical experience with the OTTAVA System, it said.

“We are proud to reach this important milestone in our robotic surgery program,” said Hani Abouhalka, the company group chairman of surgery at Johnson & Johnson MedTech.

“OTTAVA is a key innovation in our portfolio of advanced surgical technologies – all of which are designed to transform the surgical experiences across all surgery,” he added. “Our people work side-by-side with surgical teams in ORs [operating rooms] around the world every day to raise the standard of care for patients and deliver what’s next in surgery.”

Johnson & Johnson MedTech is a Warsaw, Ind.-based unit of Johnson & Johnson (J&J), which has more than 100 years of experience in medicine and surgical technology. The company said its portfolio includes robotics, wound closure, adjunctive hemostats, surgical stapling and instruments, and digital systems.

OTTAVA addresses surgical robotics shortcomings

The U.S. Food and Drug Administration (FDA) granted OTTAVA an investigational device exemption in late 2024. Johnson & Johnson MedTech said it designed the system to advance clinical innovation in general surgery, a significant part of its broader surgery business.

J&J described OTTAVA as “a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach.” The system’s unified architecture, surgical instrumentation built on J&J’s Ethicon experience, and a planned connection to the Polyphonic digital ecosystem are intended to meet the needs of each patient’s care and each surgeon’s clinical approach, the company asserted.

Johnson & Johnson MedTech first shared details about OTTAVA about four years ago. Since then, it has been relatively quiet. In October 2021, the company pushed back the platform’s development timeline by about two years, citing multiple factors.

OTTAVA’s initial design included six robotic arms. In November 2023, a J&J update included changes, including four arms to be available on demand.

SITE AD for the 2025 Robotics Summit registration.
Register now so you don’t miss out!

Johnson & Johnson MedTech preps for next steps

Dr. Erik Wilson is the chief of minimally invasive and elective general surgery at the University of Texas Health Houston and the lead investigator for the clinical study. He performed a Roux-en-Y gastric-bypass surgery using the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Center.

“Surgical robotics is at the forefront of innovation in minimally invasive surgery,” said Wilson. “I am proud to have performed the first clinical study cases with OTTAVA and potentially help advance the standard in surgical robotics.”

Johnson & Johnson MedTech plans to use data from this trial aims to support the surgical system’s ability to perform a variety of procedures. Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the U.S.

J&J said it will target an indication covering multiple procedures in general surgery within the upper abdomen. These include gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair.

“As a company operating at the intersection of biology and technology, clinical evidence generation is the core of our innovation programs to advance surgical technology for patients,” said Peter Schulam M.D., Ph.D., and chief scientific officer at Johnson & Johnson MedTech. “Through this clinical study, we are proud to be partnering with surgeons to gather evidence and support the ongoing pursuit of scientific study for the advancement of robotic-assisted minimally invasive surgery.”

The OTTAVA robotic system is under development and is not yet authorized to be marketed or sold in any market, noted J&J.

Source Link

Keep track of your essentials with the Apple AirTag 4 Pack, the ultimate tracking solution for your belongings. With over 5,972 ratings and a stellar 4.7-star average, this product has quickly become a customer favorite. Over 10,000 units were purchased in the past month, solidifying its status as a highly rated Amazon Choice product.

For just $79.98, you can enjoy peace of mind knowing your items are always within reach. Order now for only $79.98 at Amazon!

Unlock unlimited streaming with a free Amazon Prime trial!
Sign up today!

Help Power Techcratic’s Future – Scan To Support

If Techcratic’s content and insights have helped you, consider giving back by supporting the platform with crypto. Every contribution makes a difference, whether it’s for high-quality content, server maintenance, or future updates. Techcratic is constantly evolving, and your support helps drive that progress.

As a solo operator who wears all the hats, creating content, managing the tech, and running the site, your support allows me to stay focused on delivering valuable resources. Your support keeps everything running smoothly and enables me to continue creating the content you love. I’m deeply grateful for your support, it truly means the world to me! Thank you!

BITCOIN

Bitcoin Logo